Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Target Engagement, and Absorption, Metabolism and Excretion of NNC0705-0002 Following Single and Multiple Oral Administrations of NNC0705-0002 in Healthy Adults

NCT07797855 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07797855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07797855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Target Engagement, and Absorption, Metabolism and Excretion of NNC0705-0002 Following Single and Multiple Oral Administrations of NNC0705-0002 in Healthy Adults
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Recruiting
Start date
September 2, 2026
Completion date
August 1, 2027
Enrollment
112 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiometabolic diseases, healthy volunteers